Patent Application for Non-Alcoholic Steatohepatitis Diagnostic Complex
Summary
USPTO published patent application US20260108639A1 on April 23, 2026, covering a diagnostic complex for non-alcoholic steatohepatitis (NASH). The complex comprises hexa-lactoside, a metal chelator coupled to the hexa-lactoside, and a radionuclide labeling the metal chelator, enabling binding to asialoglycoprotein receptors for radiological diagnosis. The application was filed on October 21, 2024, under application number 18921265, naming six inventors including Hung-Wen YU, Mei-Hui WANG, and others.
“The complex for diagnosing non-alcoholic steatohepatitis comprises hexa-lactoside, a metal chelator coupled to the hexa-lactoside, and a radionuclide labeling the metal chelator.”
About this source
USPTO classification A61K covers pharmaceutical preparations: formulations, dosage forms, combination therapies, delivery systems, and the vehicles that carry active ingredients. Every newly published application in A61K lands in this feed, around 245 a month. Applications publish 18 months after filing, so this feed reveals what pharma formulators at major sponsors and generics were working on in the prior year and a half. Watch this if you compete in drug formulation, file freedom-to-operate analyses, scout competitive drug products before clinical readouts, or follow novel delivery platforms like nanoparticles, lipid carriers, and long-acting injectables.
What changed
USPTO published patent application US20260108639A1 covering a diagnostic complex for non-alcoholic steatohepatitis. The complex comprises hexa-lactoside conjugated to a metal chelator and labeled with a radionuclide, designed to bind asialoglycoprotein receptors for radiological imaging of NASH.
Pharmaceutical and biotechnology companies developing liver disease diagnostics should review the patent claims for potential licensing implications or freedom-to-operate concerns. The hexa-lactoside and asialoglycoprotein receptor binding mechanism described in the application represents a specific approach to NASH diagnosis that may be relevant to parties operating in the hepatology diagnostics space.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
COMPLEX FOR DIAGNOSING NON-ALCOHOLIC STEATOHEPATITIS, USE, AND CONTRAST AGENT THEREOF
Application US20260108639A1 Kind: A1 Apr 23, 2026
Inventors
Hung-Wen YU, Mei-Hui WANG, Chung-Li HO, Kun-Liang LIN, Chen-Hsin CHAN, Wan-Chi LI
Abstract
Provided herein are a complex for diagnosing non-alcoholic steatohepatitis, use of the complex, and a contrast agent comprising the complex. The complex for diagnosing non-alcoholic steatohepatitis comprises hexa-lactoside, a metal chelator coupled to the hexa-lactoside, and a radionuclide labeling the metal chelator. The complex is capable of binding to an asialoglycoprotein receptor, so that the complex has potential for use as a radiological diagnostic agent.
CPC Classifications
A61K 51/0491 A61K 51/0497
Filing Date
2024-10-21
Application No.
18921265
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.